Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota
Berberine (BBR) is an isoquinoline alkaloid extracted from Coptis chinensis that improves diabetes, hyperlipidemia and inflammation. Due to the low oral bioavailability of BBR, its mechanism of action is closely related to the gut microbiota. This study focused on the CYP51 enzyme of intestinal bact...
Saved in:
Main Authors: | Zheng-Wei Zhang (Author), Lin Cong (Author), Ran Peng (Author), Pei Han (Author), Shu-Rong Ma (Author), Li-Bin Pan (Author), Jie Fu (Author), Hang Yu (Author), Yan Wang (Author), Jian-Dong Jiang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Berberine-microbiota interplay: orchestrating gut health through modulation of the gut microbiota and metabolic transformation into bioactive metabolites
by: Tessa Dehau, et al.
Published: (2023) -
Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration
by: Ru Feng, et al.
Published: (2018) -
Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism
by: Xinyi Fang, et al.
Published: (2022) -
Berberine inhibits breast carcinoma proliferation and metastasis under hypoxic microenvironment involving gut microbiota and endogenous metabolites
by: Yanfang Sun, et al.
Published: (2023) -
Fate of Antioxidants in Gut and Interaction of Gut Metabolites and Gut Microbiota
Published: (2023)